|View printer-friendly version|
|Audentes Therapeutics Reports Fourth Quarter and Full Year 2016 Financial Results and Provides Corporate Update|
"2016 was a year of significant progress and accomplishment for Audentes," stated
Mr. Patterson continued, "We remain focused on our mission to bring transformational products to patients living with serious, life-threatening rare diseases. To that end, 2017 promises to be an exciting year. We remain on track to obtain preliminary clinical data from the Phase 1 / 2 studies in our XLMTM and Crigler-Najjar programs by year end, and continue to make important progress in the development of our Pompe and CPVT programs."
Fourth Quarter and Full Year 2016 Financial Results
For more information regarding Audentes, please visit www.audentestx.com.
Forward Looking Statements
Selected Financial Information
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/audentes-therapeutics-reports-fourth-quarter-and-full-year-2016-financial-results-and-provides-corporate-update-300421015.html